Cannabis
Stock News: Supreme Pharmaceuticals (CSE: $SL) Announces Conditional Approval
to List on the TSX.V
TORONTO, ONTARIO - April 10, 2017
(Investorideas.com Newswire) Supreme Pharmaceuticals Inc. ("Supreme"
or the "Company") (CSE:SL)(CSE:SL.CN) is pleased to announce that it
has received conditional approval from the TSX Venture Exchange
("TSX.V") to list the Company's common shares on the TSX.V.
John Fowler, President and CEO,
stated: "Graduating from the CSE to the TSX.V is an important milestone
for Supreme. We enjoyed tremendous success throughout our time on the CSE,
which provided us the flexibility we needed in the early stages of our growth.
Graduating to the TSX.V prepares us for the next steps in the development of
our cannabis business."
The Company would like to thank the
CSE for its role in Supreme's success over the past three years.
Final approval of listing on the
TSX.V is subject to Supreme satisfying certain customary conditions required by
the TSX.V. Supreme expects that it will be able to satisfy all such conditions
by mid-May 2017 and will provide an update once the TSX.V has issued a bulletin
confirming the date on which trading on the TSX.V will commence. Following
completion of all listing requirements, Supreme's common shares will be
voluntarily delisted from the Canadian Securities Exchange and will begin
trading on the TSX.V under a new symbol.
About Supreme
Supreme is a Canadian publicly traded
company committed to becoming a leading cultivator and distributor of sun grown
cannabis through its wholly-owned subsidiary 7ACRES. 7ACRES is a federally
licensed producer of medical cannabis pursuant to the Access to Cannabis for
Medical Purposes Regulations operating inside a 342,000 sq. ft. Hybrid
Greenhouse facility. The Hybrid Greenhouse combines the best technology of
indoor production with the efficiencies and sustainability of a greenhouse, in
a single large-format production footprint. Please visit www.supreme.ca and www.7acres.com for more information.
Cautionary Note Regarding Forward
Looking Statements
Certain information in this news
release constitutes forward-looking statements under applicable securities
laws. Any statements that contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. Statements in
this news release that are forward-looking statements are subject to various
risks and uncertainties concerning the specific factors disclosed here and
elsewhere in the Company's periodic filings with Canadian securities
regulators. Although the Company has attempted to identify important factors
that could cause actual results, performance or achievements to differ
materially from those contained in the forward-looking statements, other
factors could cause results, performance or achievements not to be as anticipated,
estimated or intended, including, but not limited to: dependence on obtaining
regulatory approvals; timing for completion of TSX.V approval; limited
operating history; competition; inconsistent public opinion and perception of
the medical-use marijuana industry; and regulatory or political change. There
can be no assurance that such information will prove to be accurate or that
management's expectations or estimates of future developments, circumstances or
results will materialize. As a result of these risks and uncertainties, the
results or events predicted in these forward-looking statements may differ
materially from actual results or events. Accordingly, readers should not place
undue reliance on forward-looking statements. The forward-looking statements in
this news release are made as of the date of this release. The Company
disclaims any intention or obligation to update or revise such information,
except as required by applicable law.
Neither Canadian Securities Exchange
nor the TSX Venture Exchange has reviewed, approved or disapproved the content
of this news release.
Contact Information
Investor Relations
202 - 20 De Boers Dr
Toronto ON M3J 0H1
(416) 630-7272
info@supreme.ca
www.supreme.ca
202 - 20 De Boers Dr
Toronto ON M3J 0H1
(416) 630-7272
info@supreme.ca
www.supreme.ca
More Info:
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
No comments:
Post a Comment